Spots Global Cancer Trial Database for crpc
Every month we try and update this database with for crpc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) | NCT00684970 | Metastatic Cast... | Hamsa-1™ TL-118 | 18 Years - | Tiltan Pharma Ltd. | |
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | NCT03580239 | Prostate Cancer | Everolimus Placebo | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | NCT00564928 | Prostate Cancer Prostatic Neopl... Cancer of the P... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | NCT05534646 | Castration-resi... | Apalutamide Carotuximab | 18 Years - | Cedars-Sinai Medical Center | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | NCT02793219 | Prostate Cancer | Sipuleucel-T Docetaxel | 18 Years - | The University of Texas Health Science Center, Houston | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging | NCT06276465 | Prostatic Cance... | Darolutamide 30... Stereotactic bo... Androgen depriv... | 18 Years - | UNICANCER | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01424930 | Prostate Neopla... Prostate Cancer | Abiraterone Prednisone | 18 Years - | Janssen-Ortho Inc., Canada | |
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | NCT03580239 | Prostate Cancer | Everolimus Placebo | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198 | Prostate Cancer | Abiraterone ace... Placebo Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01812746 | CRPC Prostate Cancer | BIND-014 | 18 Years - | BIND Therapeutics | |
| Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT02141438 | Metastatic Cast... | Radium-223 dich... | 18 Years - | Bayer | |
| Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer | NCT05522907 | Prostate Cancer | - | First Affiliated Hospital Xi'an Jiaotong University | ||
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | NCT00564928 | Prostate Cancer Prostatic Neopl... Cancer of the P... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Study of ES414 in Metastatic Castration-Resistant Prostate Cancer | NCT02262910 | Prostate Cancer | ES414 | - | Aptevo Therapeutics | |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer | NCT05413421 | Metastatic Pros... Neuroendocrine ... | ORIC-944 | 18 Years - | ORIC Pharmaceuticals | |
| A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | NCT02012920 | Castration-resi... CRPC | Seviteronel: gi... | 18 Years - | Innocrin Pharmaceutical | |
| Lenalidomide and Paclitaxel in Prostate Cancer | NCT00933426 | Prostate Cancer | Lenalidomide Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases | NCT02135484 | Prostate Cancer | Alpharadin | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma | NCT04567875 | Castration-resi... | No Intervention... | - | Ospedale Andrea Tortora di Pagani | |
| A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | NCT02361086 | Castration-resi... CRPC | VT-464: given o... | 18 Years - | Innocrin Pharmaceutical | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | NCT05785741 | Advanced Solid ... | DB-1310 | 18 Years - | DualityBio Inc. | |
| A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC | NCT02378870 | Prostate Cancer... | Osteodex Placebo | 18 Years - | DexTech Medical AB | |
| Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma | NCT04567875 | Castration-resi... | No Intervention... | - | Ospedale Andrea Tortora di Pagani | |
| An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | NCT02854436 | Prostatic Neopl... | Niraparib | 18 Years - | Janssen Research & Development, LLC | |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | NCT01522443 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib mitoxantrone prednisone | 18 Years - | Exelixis | |
| PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | NCT03460977 | Castration Resi... Small Cell Lung... Follicular Lymp... | PF-06821497 | 18 Years - | Pfizer | |
| A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | NCT02361086 | Castration-resi... CRPC | VT-464: given o... | 18 Years - | Innocrin Pharmaceutical | |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | NCT03685591 | Breast Neoplasm... Prostate Neopla... Neoplasms, Squa... Melanoma Mesothelioma Pancreatic Neop... Colorectal Neop... Carcinoma, Rena... Liver Neoplasms | PF-06952229 Enzalutamide | 18 Years - | Pfizer | |
| Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT02141438 | Metastatic Cast... | Radium-223 dich... | 18 Years - | Bayer | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Study of ES414 in Metastatic Castration-Resistant Prostate Cancer | NCT02262910 | Prostate Cancer | ES414 | - | Aptevo Therapeutics | |
| AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | NCT00770848 | Cancer Castrate-Resist... Mestastatic Pro... Prostate Cancer | AMG 102 AMG 102 Mitoxantrone Placebo Prednisone | 18 Years - | Amgen | |
| Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | NCT06380660 | Solid Tumor, Ad... BRCA1 Mutation BRCA2 Mutation Ovarian Cancer Breast Cancer Prostate Cancer | ACE-86225106 ta... | 18 Years - | Acerand Therapeutics Limited | |
| Testosterone in Castration-Resistant Prostate Cancer | NCT00577980 | Prostate Cancer | Testosterone | - | M.D. Anderson Cancer Center | |
| Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer | NCT01599793 | Bone Metastases Castrate-resist... Recurrent Prost... Stage IV Prosta... | cabozantinib laboratory biom... magnetic resona... | - | University of Chicago | |
| Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) | NCT01499043 | Prostate Cancer | PLX3397 | 18 Years - | Daiichi Sankyo | |
| A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | NCT02266745 | Advanced Solid ... CRPC mCRPC Metastatic Cast... PT-112 Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... | PT-112 Injectio... | 18 Years - | Promontory Therapeutics Inc. | |
| Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma | NCT04567875 | Castration-resi... | No Intervention... | - | Ospedale Andrea Tortora di Pagani | |
| Lenalidomide and Paclitaxel in Prostate Cancer | NCT00933426 | Prostate Cancer | Lenalidomide Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | NCT02793219 | Prostate Cancer | Sipuleucel-T Docetaxel | 18 Years - | The University of Texas Health Science Center, Houston | |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | NCT01522443 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib mitoxantrone prednisone | 18 Years - | Exelixis | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | NCT01637402 | Castration Resi... | Abiraterone Ace... Prednisone | 18 Years - | University of California, San Francisco | |
| Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer | NCT00916123 | Prostate Cancer | Docetaxel Prednisone 177Lu-J591 177Lu-J591 177Lu-J591 177Lu-J591 177Lu-J591 | 18 Years - | Weill Medical College of Cornell University | |
| Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) | NCT01499043 | Prostate Cancer | PLX3397 | 18 Years - | Daiichi Sankyo | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | NCT03580239 | Prostate Cancer | Everolimus Placebo | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Personalized Mini-PDX for Metastatic CRPC | NCT03786848 | Prostate Cancer | MiniPDX Group | 18 Years - | Tianjin Medical University Second Hospital | |
| Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer | NCT01558492 | Prostate Cancer | Carboplatin Paclitaxel | 18 Years - | Weill Medical College of Cornell University | |
| Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 | NCT01605227 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib prednisone | 18 Years - | Exelixis | |
| Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT02057666 | Prostatic Neopl... | Tasquinimod Placebo | 20 Years - | Ipsen | |
| Testosterone in Castration-Resistant Prostate Cancer | NCT00577980 | Prostate Cancer | Testosterone | - | M.D. Anderson Cancer Center | |
| A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01812746 | CRPC Prostate Cancer | BIND-014 | 18 Years - | BIND Therapeutics | |
| T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | NCT02113657 | Prostate Cancer | Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | NCT05534646 | Castration-resi... | Apalutamide Carotuximab | 18 Years - | Cedars-Sinai Medical Center | |
| Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | NCT05534646 | Castration-resi... | Apalutamide Carotuximab | 18 Years - | Cedars-Sinai Medical Center | |
| An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | NCT02854436 | Prostatic Neopl... | Niraparib | 18 Years - | Janssen Research & Development, LLC | |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT01083615 | Castrate-Resist... Hormone Refract... | custirsen sodiu... isotonic, 0.9% ... docetaxel cabazitaxel prednisone | 18 Years - 99 Years | Achieve Life Sciences | |
| Personalized Mini-PDX for Metastatic CRPC | NCT03786848 | Prostate Cancer | MiniPDX Group | 18 Years - | Tianjin Medical University Second Hospital | |
| Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer | NCT00901342 | Prostate Cancer | sipuleucel-T | 18 Years - | Dendreon | |
| A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01812746 | CRPC Prostate Cancer | BIND-014 | 18 Years - | BIND Therapeutics | |
| ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer | NCT00959959 | Prostate Cancer | TOK-001 TOK-001 TOK-001 TOK-001 TOK-001 TOK-001 TOK-001 TOK-001 | 18 Years - | LTN PHARMACEUTICALS, INC. | |
| Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer | NCT01478308 | Prostate Cancer | Metformin hydro... Docetaxel Prednisone | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT01083615 | Castrate-Resist... Hormone Refract... | custirsen sodiu... isotonic, 0.9% ... docetaxel cabazitaxel prednisone | 18 Years - 99 Years | Achieve Life Sciences | |
| Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198 | Prostate Cancer | Abiraterone ace... Placebo Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer | NCT01594918 | Metastatic Cast... | Cabazitaxel Mitoxantrone Prednisone Pegfilgrastim | 18 Years - | University of California, San Francisco | |
| Docetaxel Followed by Provenge in Metastatic Prostate Cancer | NCT02793765 | Prostate Cancer | Docetaxel Sipuleucel-T | 18 Years - | The University of Texas Health Science Center, Houston | |
| A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC | NCT02378870 | Prostate Cancer... | Osteodex Placebo | 18 Years - | DexTech Medical AB | |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | NCT04686682 | NSCLC SCLC CRPC ESCC Ovarian Carcino... AML MF Malignant Tumor | JAB-8263 JAB-8263 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
